Skip to main content

SOP on Case Report Form (CRF) Data Entry Procedure for Clinical Trials

 Title: Case Report Form (CRF) Data Entry Procedure for Clinical Trials


Introduction and Purpose:

Case Report Forms (CRFs) are essential documents, whether in paper or electronic format, designed to systematically record all protocol-required information and results for each participant in a clinical trial. Accurate and timely data entry into the CRF is critical for ensuring the trial's proper conduct, evaluating safety and efficacy endpoints, and forming the basis for trial-related reports and publications. This Standard Operating Procedure (SOP) establishes standards for the accurate and timely entry of data into CRFs for clinical trials, following International Council on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. These standards should be adhered to, unless the study contract or Clinical Trial Agreement (CTA) specifies more specific requirements.


Definitions and Acronyms:

  • Clinical Research: Encompasses all research involving human participants, excluding secondary studies using existing biological specimens or data collected without identifiers or publicly available data.
  • Clinical Trial: Refers to clinical research studies involving human participants assigned to an intervention designed to evaluate the effect(s) of the intervention on the participant and the effect being evaluated is a health-related biomedical or behavioral outcome.
  • CFR: Code of Federal Regulations
  • CRO: Contract Research Organization
  • CTA: Clinical Trial Agreement
  • GCP: Good Clinical Practice
  • OSP: Office of Sponsored Projects
  • PI: Principal Investigator
  • SOP: Standard Operating Procedure


Procedure:

Case Report Form Data Entry:

  • Delegated research staff, such as study coordinators, are responsible for identifying, collecting, recording, maintaining, and making available all necessary clinical trial data in the CRF.
  • All data entered into the CRF must have available source documentation, except when source data is directly transmitted into the CRF.
  • Data entry begins after the initiation of the study and the enrollment of participants and should be completed prospectively thereafter.
  • Source documentation (clinic notes, procedure reports, test results, source forms, etc.) should be created contemporaneously with the study visit or available within 2–3 business days in the Electronic Health Record system.
  • All available data should be entered into the CRF within 10 business days of the study visit that generated the data.
  • If data availability is delayed, the PI and study personnel should make efforts to acquire and enter it into the CRF as soon as possible.
  • If the study contract or CTA specifies different data entry requirements, those should be followed instead of this SOP.
  • The PI is responsible for ensuring the accuracy, completeness, legibility, and timeliness of data collected in the CRF to ensure it aligns with the protocol.
  • Every field in the CRF should be completed, and blanks should be avoided. If CRFs are in paper format, blue or black ink should be used, and pencil should never be used.

Queries and Corrections:

  • Queries and requests for changes to CRF entries are common, often following sponsor or Contract Research Organization (CRO) monitoring visits or from data management or pharmacovigilance teams.
  • Any change or correction to a CRF should be dated, initialed, and explained if necessary, and it should not obscure the original entry to maintain an audit trail. This applies to both paper and electronic CRFs.
  • Each query should be addressed, corrected, or appropriately responded to within 10 business days of notification or issuance.

Contracts and Clinical Trial Agreements:

  • During the feasibility and contract negotiation phase for new clinical trials, the study coordinator or appropriate team member should inform the Office of Sponsored Projects (OSP) program officer of the 10 business day data entry requirement outlined in this SOP. This is to prevent shorter data entry requirements from being included in the contract or CTA.

Materials Required:

  • Access to the study's paper or electronic CRF database (may require user training and logon credentials)
  • IRB-approved clinical trial protocol
  • Access to the study contract or CTA, or contact information for the responsible OSP program officer
  • Access to the Electronic Health Record and all other study source data

References:

  • 21 CFR Part 312.62: Investigator Recordkeeping and Record Retention
  • 21 CFR Part 312.68 Inspection of investigator's records and reports
  • ICH Guidance for Industry E6(R2): Good Clinical Practice 4.9

Document Approval:

Labels:

Popular posts from this blog

SOP on Investigator Delegation of Authority

Title: Investigator Delegation of Authority Introduction and Purpose: This Standard Operating Procedure (SOP) outlines the process by which the Principal Investigator (PI) delegates the authority to conduct clinical study procedures and tasks to sub-investigators and other study personnel. It also details the maintenance of documentation related to staff and investigator signatures and handwriting samples. Scope: The PI conducting a clinical trial must adhere to regulations governing informed consent (21 CFR 50) and regulations regarding Institutional Review Board (IRB) review and approval (21 CFR 56). If the study involves an investigational drug or device, additional regulations in 21 CFR 312 or 21 CFR 812 apply. Furthermore, all clinical study investigators should follow the International Council on Harmonization (ICH) guidelines for Good Clinical Practice (GCP). While these responsibilities are primarily held by the PI, they can be delegated to qualified sub-investigators and other...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

Safety Concerns for AAV Gene Therapy

 Adeno-associated virus (AAV) gene therapies have shown significant therapeutic promise, but they also carry risks, and toxicity signals are a primary safety concern. While generally well-tolerated, AAV-based therapies can trigger adverse effects ranging from immune-related responses to cellular toxicities, especially at higher doses. Here’s an overview of the key toxicity signals associated with AAV gene therapy, along with potential mechanisms and mitigation strategies: 1. Liver Toxicity Signal : Hepatotoxicity is one of the most common toxicity signals with AAV gene therapy, especially with high vector doses or in patients with pre-existing liver disease. Mechanism : AAV vectors, often targeting the liver, can cause liver inflammation due to: Immune responses to AAV capsids. Overexpression of the therapeutic transgene, leading to cellular stress. Clinical Signs : Elevated liver enzymes (ALT, AST) are common indicators of hepatotoxicity. Mitigation : Strategies include using immu...
Read more

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

ICH Topic Q5E Comparability of biotechnological/biological products (CPMP/ICH/5721/03)

 ICH Topic Q5E, as outlined in document CPMP/ICH/5721/03, deals with the comparability of biotechnological and biological products. This guideline provides a structured framework for assessing and ensuring the comparability of different product versions, including changes during development, manufacturing, or post-approval phases. The goal is to demonstrate that changes made to a product do not adversely affect its quality, safety, or efficacy. Here's an elaboration of ICH Q5E: 1. Purpose of ICH Q5E: The primary purpose of ICH Q5E is to provide guidance on how to demonstrate the comparability of biotechnological and biological products, especially when changes are made to the manufacturing process or product characteristics. Comparability studies are crucial for ensuring the consistent quality and safety of these products. 2. Types of Changes Covered: ICH Q5E covers a wide range of changes, including modifications to the manufacturing process, changes in the manufacturing site, alt...
Read more